Table 2 Summary of safety data at time of unblinding (ITT population)
From: Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
Number (%) of patients with | Masitinib (N = 27) | Placebo (N = 8) |
|---|---|---|
At least one AE (all) | 22 (81.5%) | 6 (75.0%) |
At least one AE (masitinib related) | 19 (70.4%) | N/A |
Severe AE (all) | 8 (29.6%) | 1 (12.5%) |
Severe AE (masitinib related) | 7 (26.0%) | N/A |
Serious AE (all) | 9 (33.3%) | 2 (25.0%) |
Serious AE (masitinib related) | 4 (14.8%) | N/A |
Death (all) | 0 (0.0%) | 0 (0.0%) |
AE leading to permanent discontinuation (all) | 7 (26.0%) | 0 (0.0%) |